Cargando…
Safety and immunogenicity of a randomized phase I prime-boost trial with ALVAC-HIV (vCP205) and gp160 MN/LAI-2 adjuvanted in alum or polyphosphazene
Autores principales: | O'Connell, RJ, Polonis, VR, Ratto-Kim, S, Cox, J, Jagodzinski, LL, Malia, J, Michael, NL, Excler, J, Robb, ML, Kim, JH |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441772/ http://dx.doi.org/10.1186/1742-4690-9-S2-O50 |
Ejemplares similares
-
Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand
por: Pitisuttithum, Punnee, et al.
Publicado: (2011) -
OA07-04 LB. Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial
por: de Souza, MS, et al.
Publicado: (2009) -
A Double-Blind Randomized Phase I Clinical Trial Targeting ALVAC-HIV Vaccine to Human Dendritic Cells
por: Eller, Michael A., et al.
Publicado: (2011) -
Lais /
por: France, Marie de
Publicado: (1994) -
Cyclo- and Polyphosphazenes for Biomedical Applications
por: Casella, Girolamo, et al.
Publicado: (2022)